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INTRODUCTION 
The prostate is the most common site of urological disease in 
man. It is also the male organ most commonly affected with either 
benign or malignant neoplasms. The most prevalent and clinically 
significant from of abnormal prostate growth is benign prostatic 
hyperplasia (BPH). 
The incidence is age related. The incidence of histological 
BPH in autopsy series rises from around 20% in men between 40-
50 years to 50% in men aged 51-60 years to over 90% in men older 
than 80. Although the clinical manifestations of this disease is less 
common than this, symptoms of BPH also are related to increasing 
age-25% of men report obstructing voiding symptoms at age 55. At 
the age of 75, 50% of men are symptomatic. 
The symptoms of BPH can broadly be divided into 
obstructive and irritative complaints. Obstructive symptoms of BPH 
include hesitancy, decreased force and caliber of stream, sensation 
of incomplete bladder emptying, double voiding, straining to 
urinate and post-void dribbling. Irritative voiding symptoms 
include urgency, frequency and nocturia. 
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Improved understanding of the aetiology and pathology of 
this extremely common disease has expanded the treatment options 
available to us. Alpha adrenergic blockade, 5 alpha reductase 
inhibitors, open prostatectomy, transurethral resection of the 
prostate (TURP), transurethral incision of the prostate (TUIP), 
interstitial laser therapy, transurethral electrovapourisation of 
prostate, transurethral microwave therapy, transurethral needle 
ablation of the prostate (TUNA) and high intensity focussed 
ultrasound (HFU) are some of the treatment options currently 
available. 
Despite the availability of a bewildering array of treatment 
modalities, Transurethral resection of prostate (TURP) introduced 
in the late 1920s and early 1930s, has revolutionised the treatment 
of BPH and is currently regarded as the ‘gold standard’ treatment 
for BPH, against which all other treatment modalities are evaluated. 
Currently, when surgery is performed for BPH, TURP is the 
choice in over 95% of cases. The high prevalence of symptomatic 
BPH in the aging male population, and the pre-eminence of TURP 
in its treatment has focussed attention on the after – effects of this 
form of surgery. Research has gone into the morbidity of this 
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surgery itself and its cost-burden on society. 
Traditionally, after this surgery, a foley catheter is placed 
transurethrally and is removed around the 4th post-op day. Post 
operative placement of a catheter after TURP provides for efficient 
bladder drainage after surgery, a means of bladder irrigation to 
prevent blood clots and acts as a tamponade on small bleeding 
points. Urinary retention developing after catheter removal after 
TURP may be related to persistent urethral obstruction or 
decreased/ absent detrusor contractility. Although older literature 
reports failure to void following post-TURP catheter removal (0.5-
11% of cases), there is little or no mention of the exact duration of 
catheterisation following TURP. No standardised criteria for 
removal of catheter after TURP exists in literature. 
Traditionally, the catheter is removed at around 4 days post – 
TURP. I conducted this study at our institution to help in deciding 
the interval for catheter removal following TURP, that is most 
beneficial to patients. 
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REVIEW OF LITERATURE 
BPH was first recognized as a clinical problem with a source 
in the central area of the prostate by Morgagni in 1760. It was Hugh 
Hampton Young who surgically removed this tissue nearly 100 
years later at the John Hopkins Hospital. Mc Neal’s landmark work 
elucidating the zonal anatomy of the prostate as the peripheral 
zone, the central zone, the transition zone and anterior fibro 
muscular stroma has further improved our understanding of the 
organ and its most common problem.  
The pioneering work of Davis, Alcock, Stern, Mc Carthy and 
Nesbit resulted in the introduction of transurethral resection of 
prostate (TURP) in the late 1920s and early 1930s. This was the 
first endoscopic surgery in history and revolutionised the very 
concept of how surgery can be performed. In the past century, a lot 
of research has gone into the aetiology, pathology, natural 
evolution, clinical manifestations, investigations and treatment of 
this disease.  
AETIOLOGY:  
Shapiro, in a review of the embryological development of the 
prostate, gave us insights into the aetiology of BPH. The fact that 
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the prostate is the only human organ that delays new growth until 
advanced age and that the acinar development within the prostate 
remains dormant during and after puberty, is vastly different from 
ductule acinar development in other human organs. 
The elegant work of Cunha and Chug demonstrated that 
interaction between the urogenital mesenchyme and prostatic 
epithelial cells, termed “embryonic reawakening”, plays a major 
role in prostatic growth and development. That the dog and the 
human being are practically the only two animals to develop BPH 
has been noted by researchers. These two species alone demonstrate 
an anatomical configuration in which the urethra traverses the 
prostate to enter the bladder. It is believed that the close 
relationship of these two anatomical structures and the fact that the 
passage of urine and semen, which may contain growth factors or 
carcinogens may permeate the periurethral prostatic glands, might 
be important for the development of BPH.  
Lee and colleagues postulated the intrinsic and extrinsic 
factors associated with BPH. 
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THE INTRINSIC FACTORS ARE: 
 
- Stromal element 
- Fibroblasts 
- Smooth muscle cells 
- Extracellular matrix components 
- Luminal epithelial cells 
- Basal epithelial cells. 
- Neuro endocrine factors. 
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THE EXTRINSIC FACTORS ARE:  
 
- Heredity  
- Dietary factors 
- Testicular androgens 
- Oestrogens 
- Non – androgenic endocrine factors 
- Non – testicular endocrine factors  
- Neurotransmitters.  
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PATHOLOGY 
BPH develops in the transition zone. It is a hyperplastic 
process due to an increase in number of cells. Microscopically, 
there is a nodular pattern with varying amounts of stroma and 
epithelium. Stroma is composed of varying amounts of collagen and 
smooth muscles. This dual representation of histological 
components explain the dual responsiveness to medical treatment. 
Alpha blockade may produce good results in patient with 
significant smooth muscle component while 5-alpha reductase 
inhibitors may produce a better response in BPH composed mainly 
of epithelial elements. As BPH nodules grow in the transition zone, 
a so – called surgical capsule forms when they compress the outer 
zones of the prostate. This serves as a cleavage plane in 
enucleation. 
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PATHOPHYSIOLOGY 
The pathophysiology of BPH is complex. Prostatic 
hyperplasia raises the urethral resistance, resulting in compensatory 
changes in bladder function. When outlet resistance increases, the 
elevated detrusor pressure required to maintain urine flow occurs at 
the expense of normal bladder storage function. The changes in 
detrusor function elicited by obstruction in addition with the age-
associated changes in the bladder and in the neurological system 
lead to urinary frequency, urgency and nocturia, some of the most 
important and bothersome of BPH symptoms. Thus an 
understanding of BPH pathophysiology requires an indepth 
understanding of obstruction- induced bladder dysfunction. 
BPH is a hyperplastic and not a hypertrophic process, i.e. 
there is an actual increase in the number of cells of the prostate. 
McNeal’s landmark studies demonstrate that the majority of early 
periurethral nodules are purely stromal in character. In contrast, the 
earliest transition zone nodules are from proliferation of glandular 
tissue cells. These glandular nodules appear to be derived from 
newly formed small duct branches that arise from the existing 
ducts. This gives rise to a totally new duct system. This variety of 
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neo gland formation is a very rare process outside the embryology 
of early organ formation. Thus the term ‘embryological 
reawakening’, often used to describe BPH seems to be very apt. 
During the beginning of BPH development, there is 
overwhelmingly, an increase in the number of nodules. After this 
phase, another phase of evolution occurs in which an enlargement 
of the size of the nodules occurs. There is a lot of pleomorphism in 
the ratio of stromal to epithelial tissues in BPH specimens. 
STROMAL EPITHELIAL INTERACTION 
The stromal and the epithelial cells have a paracrine type of 
communication. One class of stromal cell excretory protein 
(extracellular matrix) partially regulates epithelial cell 
differentiation. Thus defects in stromal components that usually 
serve to inhibit cell proliferation could result in benign prostatic 
hyperplasia. Many of the prostatic stromal- epithelial interactions 
both in normal development of the prostate and in benign prostatic 
hyperplasia are mediated by soluble growth factors. 
GROWTH FACTORS 
Growth factors are peptides that stimulate cell multiplication. 
Surface receptors are present on the cells that are targeted by these 
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peptides. These are in turn linked to various intracellular second 
messengers. The interactions that occur between growth factors and 
steroid hormones has the potential to change the balance of cell 
proliferation versus cell death resulting in the development of 
benign prostatic hyperplasia. Basic fibroblast growth factor (bFGF), 
fibroblast growth factor-3 (FGF-2), Acidic fibroblast growth factor 
(FGF-1), Int-2 (FGF-3), Keratinocyte growth factor (KGF, FGF-7), 
transforming growth factor β (TGF-β) and epidermal growth factor 
(EGF) have been implicated in BPH. 
It is generally accepted that growth stimulatory factors such 
as the FGF family, vascular endothelial growth factor (VEGF), and 
insulin-like growth factor (IGF) may play a role, with 
dihydrotestosterone augmenting the growth factor effects. In 
contrast to these TGF -β which is known for its inhibitory effects 
on epithelial cell proliferation, may normally exert an inhibitory 
influence over epithelial proliferation that is lost in benign prostatic 
hyperplasia. 
OTHER SIGNALLING PATHWAYS 
The sympathetic signal pathways are considered to be a vital 
part of the pathophysiology of benign prostatic hyperplasia, and the 
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evidence from this comes from the effectiveness of α-adrenergic 
receptor blockers in the treatment of benign prostatic hyperplasia. 
Alpha- adrenergic pathways modulate the smooth muscle phenotype 
in the prostate. All the components of the renin-angiotensin system 
(RAS) are present in the prostate and are activated in benign 
prosatatic hyperplasia. With the activation of sympathetic 
signalling pathways, local RAS pathways may contribute to cell 
proliferation and smooth muscle contraction. The early growth 
response gene-1 (EGR 1) transcription regulation pathway is also 
active in benign prostatic hyperplasia.  
ROLE OF CYTOKINES IN BENIGN PROSTATIC 
HYPERPLASIA 
Inflammatory cell infiltrates that are seen in many men with 
benign prostatic hyperplasia are additional sources of growth 
factors in human BPH. Peripheral blood and tumour infiltrating 
cells are known to express VEGF, a potent epithelial mitogenic 
factor. T cells secrete a variety of growth factors, including HB-
EGF and bFGF/FGF-2. Significant levels of interleukin-2, 
interleukin-4, interleukin-7, interleukin-17, interferon γ (IFN-γ) and 
their respective receptors are found in BPH tissue. Prostatic 
epithelial senelity results in increased expression of interleukin-8, 
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which promotes proliferation of non-senescent epithelial and 
stromal cells. This chronic inflammation in benign prostatic 
hyperplasia also upregulates cyclo-oxygenase 2 (COX-2) in the 
glandular epithelium. Thus inflammation pathways and cytokines 
play an important role in benign prostatic hyperplasia. 
GENETIC AND FAMILIAL FACTORS  
There is a large volume of evidence pointing to genetic 
components in benign prostatic hyperplasia. The hazard- function 
ratio for clinically evident BPH among first degree male relatives 
of BPH cases compared with the first degree male relatives of 
controls is 4.2 (95% confidence interval 1.7 to 10.2), showing a 
very strong relationship. Segregation analysis studies are consistent 
with an autosomal dominant inheritance pattern. Many cases of 
early (less than 60 years) onset clinically significant BPH could be 
attributed to heredity. In addition, monozygotic twins show a higher 
concordance rate for benign prostatic hyperplasia than dizygotic 
twins. Regression analysis studies have shown that familial benign 
prostatic hyperplasia is characterised by a large prostatic size, with 
a mean prostatic volume of 82.7ml in men with hereditary BPH 
compared with 55.5ml in men with sporadic BPH. 
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NATURAL HISTORY 
The natural history of a disease is its prognosis over time, 
ideally without treatment. The natural history of a disease is usually 
studied in prospective cohort studies wherein people affected by the 
condition are followed over time. However, practical conditions 
mean that ideal study conditions are rarely satisfied. The traditional 
model of BPH in which bladder outlet obstruction is caused by the 
physical obstruction to urine flow by the enlarged adenoma is an 
over simplistic explanation. Research into the natural history of 
benign prostatic hyperplasia contradicts this model.  
Poor correlation between symptom severity and the severity 
of urodynamic measurements of obstruction, the poor correlation 
between improvements in symptoms and improvement in degree of 
obstruction with treatment and the fact that prostatectomy is 
relatively effective at symptom relief even in the absence of 
documented obstruction all point to the fact that several other 
factors apart from the physically enlarged prostate are involved in 
patient symptomatology in BPH. 
Since even clinicians disagree about how best to define 
‘Clinical BPH’ in practice, there is as yet no widely accepted 
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epidemiological definition of a case of BPH that can be used to 
enroll patients in natural history studies. Several cohort studies 
have followed men after presentation to a urologist with clinical 
features that can be ascribed to BPH. 
In his famous study, Clarke retrospectively examined the 
outcomes in 36 men who were believed to have BPH but did not 
have absolute indications at baseline for surgery. The diagnosis was 
based on symptoms, PR findings and cystoscopy findings. The 
mean age of the patients studied was 64 years. Over an  
observational period of 3 years, 25 of the men had symptomatic 
improvement and overall 31 men had either symptomatic 
improvement or stable symptoms over almost 3 years. At the end of 
follow-up, 12 men had undergone surgery. The indications for 
surgery were not clearly defined.  
In 1968, Lytton and co-workers estimated that the chance of a 
40 year old man having a prostatectomy in his lifetime was 
approximately 10%. However, Glynn and colleagues in 1985 raised 
this estimate to 29%. Alright and associates in 1991, postulated that 
men older than 60 years had a 39% risk of requiring surgery in the 
next 20 years, men 50 to 59 years of age, a 24% chance, and men 
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40-49 years a 13% chance.  
The most common reasons for recommending intervention in 
a patient with symptoms of bladder outlet obstruction and 
irritability are that the symptoms are moderate to severe, 
bothersome and interfere with the quality of life of the patient. 
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EPIDEMIOLOGY OF BENIGN PROSTATIC 
HYPERPLASIA  
BPH is a common condition in men over 50 years of age and 
is one of the most common reasons for surgery in men of this age 
group. In the U.S alone, around 200,000 TURPs are performed 
every year. Thus, considering the aging of the general population 
due to better health care delivery world wide, BPH represents a 
significant burden on health care. 
The age – specific autopsy prevalence of histologically 
defined BPH has been shown to be relatively consistent around the 
world, regardless of ethnicity. However, rates of surgery vary 
widely among various geographic regions and among races. The 
variation stems from the lack of universally accepted diagnostic 
criteria, variations in referral patterns and wide differences among 
cultures in health care systems and willingness to seek medical 
care, aside from true potential clinical differences. 
Cross – cultural prevalence comparisons are hampered by the 
lack of a standardised case definition. Age, hormonal and 
biochemical factors, smoking, alcohol intake, medication use, 
obesity and family history have been associated with the 
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development of BPH or with surgery for BPH. Untreated, BPH can 
result in continued prostatic growth, with deterioration in urine 
flow, worsening of symptoms and decrease in quality of life. 
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CLINICAL MANIFESTATIONS  
The relationship between BPH, symptoms and obstruction 
was summarised in a simple manner by Hald and have come to be 
known as the ‘Hald rings’ 
 
The Hald rings 
The first ring in Hald rings is hyperplasia and the second is 
obstruction. A precise definition of bladder outlet obstruction is 
lacking in literature but it basically covers static and dynamic 
obstruction anatomically located at the bladder neck, the prostate 
and the urethra, and can theoretically be determined by a pressure 
flow study.  
Since the symptoms complex of ‘prostatism’ is neither 
pathognomonic for BPH, nor only related to diseases of the prostate 
(these symptoms have been described in female patients 
Hyperplasia  
Obstruction 
Symptoms 
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who obviously do not have a prostate), a more accurate and widely 
used expression is Lower Urinary Tract Symptoms (LUTS). 
Traditionally LUTS has been divided into obstructive and irritative 
symptoms. 
Obstructive symptoms can be hesitancy, decreased force or 
calibre of the stream, sensation of incomplete bladder emptying, 
double voiding, straining to pass urine and post – void dribbling. 
Irritative symptoms include urgency, frequency and nocturia.  
The self – administered questionnaire developed by the 
American urological association (AUA) is both valid and reliable in 
identifying the need to treat patients and in monitoring their 
response to therapy. This questionnaire is perhaps the single most 
important tool used in evaluation of patient with BPH. This 
assessment focuses on 7 items that ask patients to quantify the 
severity of their obstructive or irritative complaints on a scale of 0-
5. Thus, the score can range from 0 to 35. A symptoms score of 0-7 
is considered mild, 8-19 is considered moderate and 20-35 is 
considered severe. 
A physical examination, DRE and focussed neurological 
examination are performed on all patients. Note is made of the size and 
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consistency of the prostate. BPH usually results in a smooth, firm, elastic 
enlargement of the prostate. Any induration should alert the doctor to the 
possibility of cancer and the need for further evaluation.  
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THE AUA QUESTIONNAIRE 
S. 
No 
Urinary symptoms 
(Symptoms score 
criteria) 
Not 
at 
all 
Less 
than 
1 
time 
in 5 
Less 
than 
half 
the 
time 
About 
half 
the 
time 
More 
than 
half 
the 
time 
Almost 
always
1. In complete emptying: 
Over the past month how 
often have you had a 
sensation of not 
emptying your bladder 
completely? 
0 1 2 3 4 5 
2. Frequency: 
Over the past month, 
how often have you had 
to urinate again less than 
2 hours after you 
finished urinating?  
0 1 2 3 4 5 
3. Intermittency: Over the 
past month, how often 
have you found you 
stopped and started again 
several times you 
urinate? 
0 1 2 3 4 5 
4. Urgency: Over the past 
month how often have 
you found it difficult to 
post pone urination?  
0 1 2 3 4 5 
5. Weak stream: Over the 
past month, how often 
have you had a weak 
urine stream? 
0 1 2 3 4 5 
6. Straining: Over the past 
month how often have 
you had to push to begin 
urination? 
0 1 2 3 4 5 
7. Nocturia: Over the past 
month, how many times 
did you get up to urinate 
at night?
0 1 2 3 4 5 
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INVESTIGATIONS 
A urinalysis to exclude haematuria or infection and serum 
creatinine to assess renal function are required. Renal insufficiency 
may be observed in 10% of patients and warrants upper tract 
imaging. Serum PSA is considered by most clinicians to be 
optional. Upper tract imaging (Intravenous urogram or renal 
ultrasound) is recommended only in the presence of concomitant 
urinary tract disease or complications from BPH (eg.Haematuria, 
urinary tract infection, renal insufficiency, history of stone 
disease). Cystoscopy is not routinely recommended in BPH 
patients. Cystometrograms and urodynamic profiles are reserved for 
patients with suspected neurological disease or those who have 
failed prostate surgery. Measurements of flow rate, determination 
of post – void residual urine and pressure flow studies are 
considered optional.  
AVAILABLE TREATMENT OPTIONS FOR BPH  
1) Medical therapy with alpha adrenergic blockade, 5 alpha 
reductase inhibitors.  
2) A combination of the above 
3) Phytotherapy 
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4) Transurethral resection of the prostate (TURP) 
5) Transurethral incision of the prostate (TUIP) 
6) Open simple prostatectomy – suprapubic or retropubic  
7) Interstitial laser therapy 
8) Transurethral electrovapourisation of the prostate 
9) Transurethral microwave therapy (TUMT) 
10) Transurethral needle ablation (TUNA) 
11) High – intensity focussed ultrasound (HIFU) 
Of all these, TURP is considered the ‘gold standard’ 
treatment for BPH. 
 25
TRANSURETHRAL RESECTION OF THE PROSTATE 
The introduction of TURP in the early 1900s where a 
prostatectomy is conducted without the typical and painful incision 
and associated convalescence was a milestone in the history of 
urology. Today TURP has nearly replaced open prostatectomy, 
which is currently reserved for patients with prostates too large to 
resect, for patients with co-existent bladder disease managed 
concurrently with the prostatectomy, and for those few men with 
orthopaedic disabilities which preclude their being placed in a 
proper dorsal lithotomy position. 
For decades the dominant major surgery performed by 
urologists, TURP is being severely challenged by the advent of an 
array of new strategies in BPH management-both medical and 
invasive therapies. Further the studies of Wasson and Co-workers 
has enhanced the concept of ‘watchful waiting’ in BPH. 
Yet, though several treatment strategies have been deviced 
and continue to be published, almost all authors continue to refer to 
TURP as the ‘gold standard treatment’ for BPH. Even in this era of 
breath taking medical innovations, this operation continues to be 
the benchmark against which all other treatments are assessed. 
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Most urologists regard TURP as the most difficult and most 
important of all elective urological operations. TURP retains the 
same severe learning curve that existed when it was first performed 
almost a hundred years ago. 
Patient selection for TURP is important for its success. It is 
vital that cases of prostatic cancer be excluded before undertaking a 
TURP for presumed benign disease. The available diagnostic tools 
to achieve this exclusion include the DRE and the serum PSA, 
along with its various derivatives-age- adjusted PSA, free Vs 
complexed PSA, PSA velocity and PSA density. 
In the properly selected patient, no therapy equals the 
potential for durable symptom relief as does TURP, except for open 
prostatectomy, whose higher morbidity has confined its utility to 
specific defined indications. Indications for TURP include absolute 
and relative. 
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ABSOLUTE INDICATIONS FOR TURP IN BPH ARE 
 
1) Recurrent urinary tract infection 
2) Refractory haematuria 
3) Upper tract damage 
4) Secondary vesical calculi 
5) Urinary retention that fails trial voiding 
However, the vast majority of men undergoing TURP do so 
for symptom relief. Today these are often men who have failed 
medical therapy. In a 1997 AUA- Gallup survey, most American 
urologists suggested medical management as their initial 
therapeutic intervention in BPH. These data and mounting 
worldwide sales of alpha blockers and 5 alpha reductase inhibitors 
document the enormous shift to medical management as at least 
first therapy for BPH. Given the at least initial success rates of 
medical management, it would seem reasonable that today TURP be 
reserved for those men who have failed a trial of medical 
management unless, when presented with the option of currently 
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existing treatments along with their respective probabilities of 
outcome, the patient selects the very high likelihood of an 
immediate successful result offered by TURP. Wasson and 
colleagues reported in their prospective randomised trial of TURP 
Vs “Watchful Waiting”, that outcomes of surgery were best for men 
who were most bothered by their urinary symptoms at baseline.  
No data exist to support a concept of early TURP, i.e.  
operating at a young age and thus avoiding future urological 
complications and the need of operating upon an older patient who 
is infirm.  
In the evaluation of men with LUTS, there has occurred a 
recent shift away from the traditional ‘hard’ parameters of 
assessment (Flowrates, residual urines, urodynamic studies, 
cystoscopy, sonography and IVU) to the “Soft” parameters 
(Symptom indices and bother indices). Indeed the latter have 
become the more relevant in the selection of therapy, especially 
TURP. The availability of the AUA symptom score and the BPH 
impact index have provided tools to quantitate the severity of 
symptoms and their impact on the  patient’s quality of life, thus 
placing stress on the  concept that therapy  makes the greatest sense 
 29
in those most bothered.  
Once the decision for surgery has been made, the volume of 
the prostate becomes an essential factor. Many urologists favour 
Trans – urethral incision of the prostate (TUIP) over TURP in men 
with prostrates of small volume. The AHCPR guidelines share this 
view and regard TUIP as an underutilised procedure in BPH. 
Likewise, it is equally important for the urologist to determine pre 
operatively that the patient’s prostate is not so large as to exceed  
his resecting capacity. Embarking on TURP on a gland that is too 
large for this procedure can end in a “Channel TURP” result, 
excessive bleeding or other major complications. Also, it is 
important that the patient undergoing TURP be advised in details 
by his urologist of the procedure’s intended objectives and its 
recognised complications. 
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SURGICAL TECHNIQUE 
There are certain essential principles in performing a TURP. 
First, the surgeon should establish and then rigidly follow a single 
routine sequence of resection. The urologist must at all times 
maintain within his mind a three dimensional image of the prostate 
and its surrounding structures. The resection should preferably 
produce long thick chips of large volume. It should be the objective 
of the resectionist to remove the great bulk of the prostatic 
adenoma, essentially replicating the enucleation achieved with open 
prostatectomy. On the other hand, it is not necessary, nor indeed is 
it desirable, to be a fanatical “capsule seeker”. A residual thin rim 
of adenoma next to the surgical capsule is preferable to cutting too 
deep and creating capsular perforations. The resection and 
establishment of reasonable haemostasis must be completed in one 
area of the operation before proceeding to the next. It must be 
remembered that the verumontanum is the distal land mark of the 
resection. The appearance of the external urethral sphincter must be 
recognised by the surgeon. This important structure must not be 
harmed. 
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COMPLICATION OF TURP 
1) Bleeding 
2) TURP Syndrome 
3) Rectal perforation  
4) Anaesthesia – related complications 
5) Post – op urinary retention 
6) Infection  
7) Bladder neck contracture  
8) Urethral stricture  
9) Incontinence  
10) Impotence 
11)  Retrograde ejaculation 
Technological improvements in lighting, resectoscope design, 
lens crafting, anaesthetic care, surgical technique and improved 
antibiotics have greatly improved the morbidity profile of TURP. 
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THE SALINE TURP 
The most important disadvantage of standard monopolar 
TURP is the requirement of hypotonic irrigating solution that carry 
the risk of dilutional hyponatraemia and TURP syndrome. Bipolar 
TURP was developed to allow the operation to be performed in a 
normal saline environment and theoretically allow for longer and 
safer resection. The traditional monopolar TURP uses an active 
electrode loop to transmit energy into tissue and a return electrode 
at the skin to complete the circuit. The electrical resistance creates 
temperatures as high as 4000c. Bipolar technology allows high 
initialising voltage to establish a voltage gradient in the gap 
between two electrodes. In essence, the active and return poles are 
incorporated into the electrode design. This energy converts the 
conductive medium (Saline) into a plasma field of highly ionised 
particles. This field disrupts the molecular bonds between the 
tissues, allowing the high – temperature loop to provide rapid 
vapourisation and desiccation of prostate tissue and result in a “Cut 
and Seal” effect. This effect supposedly reduce resection times. 
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CATHETERS AFTER TURP 
Post- operative catheterisation following trans-urethral 
resection of prostate provides for efficient bladder drainage after 
surgery, a means by which the bladder can be irrigated to prevent 
blood clots, and also as a tamponade on small bleeding points. 
Catheters differ in size, shape, types of material, number of lumens 
and types of retaining mechanisms. Large – caliber catheters are 
used to evacuate potential blood clots after TURP. Triple lumen 
catheters have smaller lumens than two- way catheters. However 
these provide vital bladder irrigation after TURP and hence are 
traditionally inserted transurethrally after a TURP procedure. The 
rigidity of the catheter, the ratio between internal and external 
diameters and the bio compatibility depend on the material with 
which the catheter is made. Mucosal irritation is reduced when 
catheters with a low co-efficient of friction are used. A 22 French 
three way Foley urethral catheter is the standard catheter chosen by 
most urologists after TURP.   
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STUDY DESIGNS IN BPH 
Many clinical studies in BPH are of high quality, but some 
still contain deficiencies in design, conduct, analysis or 
presentations. Some qualify as only ‘pilot studies’. Hence certain 
general criteria have been laid down in urological literature for 
studies involving BPH. These are (1) lack of bias (2) an adequate 
number of subjects (3) appropriate and sensitive methods of 
evaluation and (4) statistical variation. Bias usually does not 
constitute a problem. However, unconscious or conscious bias can 
occur either in the assignment or choice of patients. 
A number of primary considerations are relevant to sample 
size: (1) The natural history of BPH (2) The magnitude of 
difference expected if a positive result occurred due to intervention 
(3) The desired level of statistical significance (4) The standard 
deviation expected and (5) The number of dropouts expected. The 
size must be sufficient to prove or disprove a hypothesis or 
hypotheses and presumably to detect clinically important changes. 
However, the sample size should not be so large as to make small 
and clinically insignificant differences significant from a statistical 
stand point. In considering objective changes, the concept of 
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clinical versus statistical significance must be kept in mind. 
Subjective variables are difficult to quantify, and many such 
variables are often graded according to severity and the resultant 
changes in grade subjected to analysis, either separately or in 
groups. Lead-in period, data variables, stratification, patient 
priorities and meta-analysis are some of the other considerations in 
studies conducted in BPH. 
 36
AIMS AND OBJECTIVES 
1) To observe the patient after removal of urethral catheter on 
POD – 2 and POD – 4 after TURP for BPH 
2) To assess which modality (POD – 2 removal Vs POD -4 
removal of catheter) has overall benefits for the patient 
undergoing TURP. 
3) To compare the outcome parameters in both groups- like 
post-op PVR and uroflowmetry and the complication profile. 
4) To know whether the early removal of catheter in post-TURP 
patients will be beneficial when compared to the conventional 
4th day catheter removal, since keeping a large diameter 22F 
foley catheter is often very inconvenient for the patient. 
5) To know whether post-TURP complications are reduced by 
early removal of catheter. 
 37
DESIGN OF STUDY  
Period of study : 2009-2012  
Number of Patients studied : 68 
Age range : 45-85 years 
Common presentations : Straining to void   
Irritative voiding symptoms 
AUR  
Refractory Haematuria  
Investigations : Urine analysis 
Urine Culture 
Complete blood count 
USG KUB with Prostate Size, 
PVR estimation 
XRay KUB 
Uroflowmetry 
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INCLUSION CRITERIA: 
1. All BPH patients admitted to ward and planned for TURP 
were counselled. Patients giving consent to be part of the 
study were selected. 
EXCLUSION CREITERIA: 
The following category of patients were excluded from the 
study: 
1) Diabetics 
2) patients with history of cerebrovascular accidents 
3) Co-existent stricture urethra 
4) Those who were subjected to a simultaneous endoscopic 
procedure like cystolitholapaxy or internal urethrotomy.  
5) Patients with biopsy proven prostate cancer (undergoing 
channel TURP) were excluded.  
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MATERIALS AND METHODS 
A total of 68 patients were enrolled in the study. Age, size of 
the prostate (as determined by USG KUB), P.R grade of prostate, 
cystoscopic grade at TURP were recorded. Patients were assigned 
to POD – 2 and POD – 4 groups. Standard TURP was performed on 
all patients. A 24 french resectoscope was used with routine 
precautions taken to achieve maximum haemostasis without undue 
prolongation of resection time. Immediately after surgery, all 
patients had a 3 way foley urethral catheter placed with saline 
irrigation. 
The patients were basically divided into two groups. Group I 
included patients in whom the catheter was removed on POD – 2 
and Group – II included patients in whom catheters were removed 
on POD-4 
After removal of catheter, the patients were observed and 
outcomes carefully recorded. Parameters like uroflowmetry and 
PVR were recorded post-op, evaluated and compared. 
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PHOTOGRAPHS 
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RESULTS 
Table-1: Age distribution of patients 
Age Group 
(Years) POD-2 Wing POD-4 Wing P Value 
45-60 5 13 
0.084 60-70 18 12 
> 70 years 11 9 
 
Fig-1: Age distribution of patients 
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Table-2: Patients who developed retention after catheter removal 
Group Total Patients 
Patient with post 
catheter removal 
urinary retention 
(requiring re-
catheterisation) 
Percentage P Value 
POD-2 
Group 
34 4 11.76% 
1.000  
(Not 
significant)POD-4 
Group 
34 4 11.76% 
 
Fig-2: Patients who developed retention after catheter removal 
11.76% 11.76%
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Table-3: Patients who had transient bothersome irritative symptoms 
after removal of catheter 
Group Total 
Those who developed 
irritative voiding 
symptoms (dysuria) 
after catheter removal 
Percentage P Value 
POD-2 
Group 
34 4 11.76% 0.493  
(Not 
significant)
POD-4 
Group 
34 6 17.64%  
 
Fig-3: Patients who had transient bothersome irritative symptoms after 
removal of catheter 
Patients who had transient bothersome irritative symptoms after removal of 
catheter
11.76%
17.64%
0.00% 2.00% 4.00% 6.00% 8.00% 10.00% 12.00% 14.00% 16.00% 18.00% 20.00%
POD-2 Group
POD-4 Group
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Table-4: Patients who developed transient urgency/ incontinence after 
catheter removal 
Group Total 
Urgency/ Incontinence 
Patient who developed 
transient 
urgency/incontinence 
after catheter removal 
Percentage P Value 
POD-2 
wing 
34 2 5.8% 
0.642 (Not 
significant)
POD-4 
wing 
34 3 8.8% 
 
Fig-4: Patients who developed transient urgency/ incontinence after 
catheter removal 
Patients who developed transient urgency/ incontinence after catheter removal
5.80%
8.80%
POD-2 wing POD-4 wing  
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Table-5: Average Post Op PVR 
Group Mean PVR on day 5 after surgery (ml) 
Standard 
deviation P Value 
POD-2 
wing 
18.38 25.46 
0.843 (Not 
significant) 
POD-4 
wing 
19.56 23.36 
 
Fig-5: Average Post Op PVR 
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CONCLUSION 
Our study shows that early catheter removal after TURP is 
beneficial to the patient and does not increase the complication 
profile. This is supported by the following data. 
Over all 11.76% patients in the POD-2 group and 11.76% 
patients on the POD-4 group developed retention of urine after 
catheter removal that required recatheterization. Those who failed 
catheterization (developed retention) in either group were 
recatheterized and discharged with catheter. Catheter removal was 
done as an outpatient procedure around 7 days later. No patient in 
our study had to be on catheter beyond this period. 
In the POD-2 group 4 patients developed retention requiring 
recatheterization. In the POD-4 group 4 patients developed 
retention requiring recatheterization. There was no statistically 
significant increase in recatheterisation rate in the POD-2 group, 
suggesting that urinary retention does not develop at a higher rate 
when early (POD-2 Vs POD-4) catheter removal is practiced after 
TURP. 
The average Post-Op PVR was 18.38ml in the POD-2 group 
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and 19.46ml in the POD-4 group. This average PVR was not higher 
in the POD-2 group when compared with the other group. 
After catheter removal, some patients in our study developed 
transient urgency/ urge incontinence. Again no statistically higher 
urgency/ incontinence rate was recorded in the POD-2 group. 
Some patients reported bothersome increased frequency after 
catheter removal Post- TURP. This parameter too was not reported 
at any higher rate in POD-2 group than the POD-4 group. 
A question “on a scale of 0-100, how satisfied are you with 
the treatment for your condition?” was posed to all patients in the 
study. The POD-2 group patients reported higher scores than the 
POD-4 group. This is probably related to lesser patients discomfort, 
lesser requirements for analgesia and earlier discharge from 
hospital in this group. 
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DISCUSSION 
Rate of recatherization after catheter removal Post-TURP 
surgery is reported in literature to occur in 0.5-11% of patients. The 
most common cause for this has been ascribed to hypotonic bladder 
in literature. It is postulated that age older than 80 and low maximal 
detrusor pressure are significant predictors to post-op failure to 
void after catheter removal. 
The interval to catheter removal after TURP has decreased 
significantly in the past 2 decades. The benefit from such a 
decrease is medical, with a theoretical reduction of known 
complications of an indwelling catheter (Stricture and infection). 
Our study shows that reduction in catherization periods Post-
TURP, is not detrimental to the patients and can in fact be of 
beneficial value (better patient satisfaction, reduced hospital stay, 
reduced infection from an indwelling catheter, reduced post 
operative discomfort and reduced requirements for analgesia). Early 
removal of catheter did not increase the morbidity and maintained 
the efficiency of the procedure. 
Our study analysed various parameters like post-op PVR, 
bothersome urgency, bothersome frequently post-catheter removal 
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urinary retention etc. All these parameters were statistically similar 
in POD-2 group as in POD-4 group. No statistically significant 
increase in complication profile was demonstrated in POD-2 group. 
Hence it would seem reasonable that after TURP, catheter removal 
on the second post-op day can generally be adopted. 
If this practice is adopted as routine, the savings resulting 
from the reduction in hospital stay would be considerable. Also the 
patient comfort and acceptance of this procedure (TURP) would 
increase. 
 
 53
MASTER CHART 
POD IV WING OF STUDY 
S. 
No Patient’s  Name 
IPSS 
score 
Prostate 
Volume 
Pre op 
Uroflow 
Pre op 
PVR 
P.R. 
Grade 
Cystoscopy Grade at 
TURP DOS 
Catheter 
removed on 
Post – op 
PVR Post Op uroflow Course After Catheter removal 
1. Senkaiyan  
60 / M IP:17240 
18 55CC Qmax-6 
Qavg-3 
200 ml III Gr III left lateral Gr II 
R.Lateral & Median  
23.05.11 POD IV 50 ml Qm-11 
 
Qavg-7 
 
Developed dysuria -treated with antibiotics 
symptom free on discharge 
2. Durairaj  
52/M  
IP:19866 
21 35CC AUR AUR II Gr II lateral lobes 13.06.11 POD IV Nil Qm-16 
 
Qavg-13 
 
Uneventful 
3. Venkatachalam 
75/M 
IP:20930 
20 43CC Qm-6 
Qavg-3 
200 ml III Gr II trilobar enlargement 22.06.11 POD IV Nil Not done as pt 
unco operative  
C/o In continence  
- Taught Kegel’s exercise 
- Was symptom free on  discharge   
4. Krishnan 
70/M 
IP: 21659 
27 60CC Qm-5 
Qavg-2 
100ml III Gr II trilobar enlargement  24.06.2011 POD IV 40 ml Qmax-9 
Qavg-7 
C/o dysuria – Treated with antibiotics, was 
symptom free at discharge  
5. Bakthavachalam 
60 yrs/M 
IP 22126 
19 70CC Qm-7 
Qavg-4 
150ml II Gr II Lateral Lobes 13.02.11 POD IV 35CC Qm-9 
Qavg-7 
Developed retention -recatheterised 
6. Kaliappan 
74/M 
IP: 25345 
24 35CC Qmax-7 
Qavg-4 
150ml II Gr II Lateral Lobes 15.3.11 POD IV 50 ml Qm-10 
Qavg-7 
C/o Transient 
Urgency after catheter removal, was symptom 
free on discharge  
 
7. Perumal Raj  
75/M 
IP No: 25347 
24 45CC AUR AUR II Gr III Left Lateral  
Gr II R.Lateral & Median 
22.3.11 POD IV Nil Qm-10 
Qavg-7 
Developed Retention recathcterised  
8. Kattaiyan  
45/M 
IPNo: 27238 
19 52 CC AUR AUR III Gr II trilobar enlargement  3.08.11 POD IV 50 ml Qm-16 
Qavg-13 
C/o Occasional Haematuria, was symptom 
free on discharge 
9. Nova  
56/M 
IP No: 28038 
15 35CC Qm-9 
Qavg – 6 
100 ml II Gr II 
Lateral Lobes 
3.8.11 POD IV Nil Qm-14 
Qavg-11 
C/o Dysuria 
Treated with Antibiotics symptom – free on 
discharge 
10. Ponnukannu 
67/M 
IP: 25970 
13 42CC AUR AUR II Gr II trilobar enlargement  5.8.11 POD IV Nil Qm-12 
Qarg – 10 
C/o dysuria treated with antibiotics, was 
symptom free on discharge 
11. Varadhan 
73/M 
IP: 27624 
21 48CC Qm-7 
Qavg-4 
NIL III Gr III  
left lacteral 
Gr II R.Lateral & Median 
10.8.11 POD IV Nil Qm-9 
Qavg-7 
C/o Incontinence 
Taught Kegel’s  
Exercises. Symptom free on discharge 
12. Nicolas  
60/M 
IP: 27623 
22 50CC Qm-6 
Qavg-3 
100ml II Gr II trilobar enlargement  10.08.11 POD IV Nil Qm-12 
Qavg-10 
C/o Difficulty in voiding Treated with α 
blockers. Symptom free on discharge 
13. Kuppan  
50/M 
IP: 25340 
17 30CC Qm-8 
Qavg-5 
150ml II Gr II 
left lateral Gr I 
R.lateral 
17.8.11 POD IV 50ml Qm-12 
Qavg-10 
C/o Dysuria Treated with Antibiotics 
symptom – free on discharge 
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S. 
No Patient’s  Name 
IPSS 
score 
Prostate 
Volume 
Pre op 
Uroflow 
Pre op 
PVR 
P.R. 
Grade 
Cystoscopy Grade at 
TURP DOS 
Catheter 
removed on 
Post – op 
PVR Post Op uroflow Course After Catheter removal 
14. Munusamy 
58/M 
IP: 29265 
 
22 35 CC Qm-9 
Qavg-7 
100ml II Gr II trilobar 19.08.11 POD IV Nil Qm-12 
Qavg – 10 
Uneventful 
15. Radhakrishnan 
58/M 
IP: 28041 
24 40CC AUR AUR II Gr II  
trilobar 
26.08.11 POD IV Nil Qm-14 
Qavg-12 
Uneventful 
16. Kannu 
67/M 
IP:30082 
20 35CC Qm-6 
Qavg-4 
150 ml III Gr II 
trilobar 
26.08.11 POD IV Nil Qm-11 
Qavg-8 
Uneventful 
17. Moorthy 
50/M 
IP: 30499 
24 40cc Qm-9 
Qavg-7 
150 ml II Gr II 
trilobar 
02.09.2011 POD IV 20 ml Qm-10 
Qavg-7 
C/o Difficulty in voiding, treated with α 
blocker was symptom free on discharge  
18. Kumar  
60/M 
IP:27634 
23 35CC AUR AUR I Gr I 
Lateral lobes 
02.09.2011 POD-IV Nil Qm-10 
Qavg-8 
Developed Retention -Recatheterised 
19. Ramalingam 
67/M 
IP:30615 
29 44CC Qm-9 
Qavg-5 
100ml II Gr II 
Trilobar 
14.09.11 POD IV 50 ml Qm – 10 
Qavg-7 
C/o, difficulty in voiding treated with α 
blocker was symptom free on discharge 
20. Shanmugam 
55/M 
IP:1150 
31 50CC Qm-8 
Qavg-6 
Nil II Grade II 
Left Lateral  
Gr I 
Right Lateral  
12.10.11 POD IV Nil Qm-9 
Qavg – 6 
C/o Dysuria, Treated with Antibiotics 
21. Mohan  
55/M 
IP:34903 
30 50CC Qm-10 
Qavg-6 
Nil II Gr II 
Trilobar 
14.10.11 POD IV Nil Qm-11 
Qavg-8 
Uneventful 
22. Chinnaiyan 
60/M 
IP:38269 
28 58CC AUR AUR III Grade III 
Lateral lobes 
09.11.11 POD IV 30 ml Qm-8 
Qavg-8 
Uneventful 
23. Palayam 
70/M 
IP:38544 
32 62CC Qmax-7 
Qavg-5 
200 ml III Grade II 
Lateral lobes  
09.11.11 POD IV 50 ml Qm-8 
Qavg-6 
C/o difficulty in voiding treated with 
α blockers, was symptom free on discharge 
 
24. dhanapal  
70/M 
IP 390622 
34 69CC Qm-6 
Qavg-3 
200 ml III Grade III Lateral lobes  
Grade II 
Median Lobe 
11.11.11 POD-IV 50ml Qm-8 
Qavg-6 
C/o difficulty in voiding treated with α 
blockers was symptoms free on discharge 
25. Buhari 
60/M 
IP:41468 
28 70CC AUR AUR III Grade III Lateral Lobes 2.12.11 POD-IV Nil Qm-10 
Qavg-8 
Uneventful 
26. Selvaraj 
58/M 
IP:40997 
26 68CC Qmax-8 
Qavg-6 
Nil II Grade II trilobar 2.12.11 POD IV Nil Qmax-9 
Qavg-7 
Uneventful 
27. Duraivel  
58/M 
IP: 40997 
19 60CC AUR AUR II Grade II Lateral lobes 07.12.11 POD IV 25 ml Qmax-9 
Qavg-7 
Developed Retention Recathcterised 
28. Subramani 
70/M 
IP:41882 
17 34CC Qm-9 
Qavg-7 
Nil I Grade II Lateral Lobes 9.02.11 POD IV NIl Qmax-10 
Qavg-8 
Uneventful 
29. Ravichandran 
45/M 
IP:43547 
28 38CC Qm-10 
Qavg-6 
Nil II Grade II trilobar 14.12.11 POD IV Nil Qmax-11 
Qavg-7 
Uneventful 
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S. 
No Patient’s  Name 
IPSS 
score 
Prostate 
Volume 
Pre op 
Uroflow 
Pre op 
PVR 
P.R. 
Grade 
Cystoscopy Grade at 
TURP DOS 
Catheter 
removed on 
Post – op 
PVR Post Op uroflow Course After Catheter removal 
30. Samundu 
65/M 
IP:43556 
34 42CC AUR AUR II Grade II Lateral 28.12.11 POD IV 50 ml Qmax-9 
Qavg-8 
C/o difficulty  
in voiding - 
Treated with α blocker, was symptom free on 
discharge  
31. Sridhar 
65/M 
IP 44457 
32 45CC AUR AUR II Grade II trilobar 20.1.12 POD IV Nil Qmax-10 
Qavg-8 
Uneventful 
32. Vijjayan  
72/M 
IP:2183/12 
 
31 50CC Qmax-9 
Qavg-7 
150 ml II Grade III 
Lateral lobes 
25.1.12 POD IV 50 ml Qmax-11 
Qavg-7 
Uneventful 
33. Sengaiyan 
60/M 
IP:2163 
30 40CC Qmax-9 
Qavg-6 
100ml II Grade II 
trilobal 
1.2.12 POD IV 50ml Qmax-10 
Qavg-8 
Uneventful 
34. Kasinathan 
56/M 
IP:2644212 
22 44CC Qmax-11 
Qavg-7 
150 ml II Grade II Lateral Lobes 3.2.12 POD IV 50 ml Qmax-12 
Qavg-8 
Uneventful 
POD II WING OF STUDY 
S. 
No Patient’s  Name 
IPSS 
score Prostate Volume 
Pre op 
Uroflow Pre op PVR 
P.R. 
Grade 
cystoscopy 
Grade at TURP DOS 
Catheter 
removed on 
Post – op 
PVR Post Op uroflow Course After Catheter removal 
1. Kannaiya 
77/M 
IP:15003 
20 40CC Qmax-7 
Qavg-4 
150 ml II Gr II Lateral 
Lobes 
06.05.2011 POD II Insignificant Qm-12 
 
Qavg-9 
 
Catheter removed on 2nd POD uneventful 
2. Dakshina 
moorthy  
63/M 
IP:16022 
19 43CC AUR AUR III Gr II trilobar 20.5.11 POD II 50ml Qm-10 
Qavg-7 
Uneventful  
3. Rajagopal  
61 yrs/M 
IP:16477 
24 48CC AUR AUR Ii Gr II Lateral 
lobes 
25.5.11 POD II 30 ml Qm-13 
Qavg-9 
Uneventful 
4. Lakshmanan 
72/M 
IP:16468 
21 30cc Qmax-4 
Qavg-2 
250CC II Gr II 
Left Lateral  
Gr I Right lateral  
25.5.11 POD II 50 ml Qm-10 
Qavg-7 
Uneventful 
5. V.Govindasamy 
70/M 
IP:16344 
26 52CC Qm-6 
Qavg-3 
100cc III Gr III 
Lateral Lobes 
Gr.I Median lobe 
30.5.11 POD II Insignificant  Qm-9 
Qavg-7 
C/o Occasional haematuria – 2nd Pod 
No C/o from 3rd POD 
6. Chinnaiyan  
85 / M 
IP:19286 
27 60cc Qm-4 
Qavg-2 
200ml III Gr III left lateral  
Gr II Rt lateral  
Gr II Median 
20.6.11 POD II 45 ml Qm-9 
Qavg-6 
C/o dysuria treated with antibiotics no C/o on 
discharge 
7. Krishnan 
65/M 
IP:21804 
18 38CC AUR AUR II Gr II Trilobar 
enlargement 
23.6.11 POD II Nil Qm-12 
Qavg-9 
Uneventful 
8. Duraisamy 
62/M 
IP: 19018 
24 43CC Qm-7 
Qavg-4 
Insignificant III Gr II Lateral 
lobes 
23.06.11 POD II Nil  Qm-15 Qavg-12 Uneventful 
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S. 
No Patient’s  Name 
IPSS 
score Prostate Volume 
Pre op 
Uroflow Pre op PVR 
P.R. 
Grade 
cystoscopy 
Grade at TURP DOS 
Catheter 
removed on 
Post – op 
PVR Post Op uroflow Course After Catheter removal 
9. Kathambarajan  
75/M 
IP:24039 
19 30CC Qm-12 
Qavg-9 
Insignificant I Gr I Lateral lobes 11.7.11 POD II Nil Qm-15 
Qavg-12 
Uneventful 
10. Abubacker 
54/M 
IP: 27523 
21 33CC AUR AUR GII GII lateral lobes 8.8.11 POD II NIl Qm-15 
Qavg-11 
C/o Dysuria Treated with Antibiotics no C/o 
on discharge 
11. jayaraman 
62/M 
IP:26673 
14 49CC AUR AUR GII GII trilobar 
enlargement 
11.08.11 POD II 35ml Qm-11 
Qavg-8 
C/o Occasional haematuria / dysuria. Treated 
with antibiotics no c/o on discharge 
12. Madhavalu 
50 yrs 
IP:28597 
21 29CC Qmax-10 
Qavg-7 
Nil GI GI lateral lobes 18.8.11 POD II Nil was not possible 
as VV less than 60 
ml 
C/o difficulty in voiding, was treated with α 
blockers recovered and had no complaints at 
discharge 
 
13. Mohideen  
69/M 
IP:28595 
29 43CC AUR AUR II Gr II trilobar 
enlargement  
25.8.11 POD II 80 ml Was not possible 
as VV law 
C/o difficulty in voiding, treated with α 
blockers. Was symptom free on discharge 
14. Ayyakannu  
60/M 
IP:28598 
31 60VV AUR AUR GII G II Lateral lobes 25.08.11 POD II 75 ml Qm-9 
Qavg-7 
C/o difficulty in passing urine. Treated with 
α blockers was symptoms free on discharge 
15. Philominraj 
74/M 
P:30638 
28 35CC (outside 
USG report 120 
CC) 
Nil Qmax-6 
Qavg-4 
I Gr II Lateral 
lobes 
25.08.11 POD II Nil Qm-11 
Qavg-7 
Uneventful 
16. Govidan  
60/M 
IP:30767 
14 52CC Nil Qmax-5 
Qavg-3 
III Gr II 
trilobar 
enlargement 
05.09.11 POD II Nil Qm-7 
Qavg-5 
C/o difficulty in voiding treated with α 
blockers symptom free at discharge 
17. Ranganathan 
75/M 
IP:30767 
21 38CC 60ml Qmax-5 
Qavg-2 
II Gr.II lateral lobes 19.09.11 POD II Nil Qm-7 
Qavg-5 
Uneventful 
18. Ali Hossain 
70/M 
IP:37732 
24 53CC Qmax-10 
Qarg-6 
100ml III Gr II 
trilobar 
31.10.11 POD Ii Nil Qmax-12 
Qavg-10 
Developed retention recatheterised 
19. Krishnan samy  
61/M 
IP:39304 
 
 
21 60CC Qmax-8 
Qavg-5 
150CC II Grade II Lateral 
lobes  
07.11.11 POD II Nil Qmax-9 
Qavg-7 
Developed Retention recatheterised  
20. Chandriah  
65/M 
IP:39457 
19 48CC AUR AUR II Grade II Lateral 
lobes  
Grade I  
Median Lobe 
17.11.11 POD II 50ml Qmax-14 
Qavg-12 
Uneventful 
21. Rajamanickam 
65/M 
IP:40256 
30 35CC Qmax-9 
Qavg-5 
180 ml I Grade II left 
Lateral  
Grade I Right 
Lateral  
21.11.11 POD II Nil Qmx-10 
Qavg-8 
Uneventful 
22. Mohadmeeran 
76/M 
IP:40504 
31 42CC AUR  AUR II Grade II trilobar 21.11.11 POD II 30 ml Qmax-14 
Qavg-10 
C/oDysuria, treated with Antibiotics 
23. Chinna Thambi  
70/M 
IP:41553 
27 40CC Qmax-7 
Qavg-3 
250 ml II Grade II trilobar 24.11.11 POD II Nil Qmax-12 Qavg-8 C/o.Incontinence- taught kegels exercises, 
was symptom free on discharge  
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S. 
No Patient’s  Name 
IPSS 
score Prostate Volume 
Pre op 
Uroflow Pre op PVR 
P.R. 
Grade 
cystoscopy 
Grade at TURP DOS 
Catheter 
removed on 
Post – op 
PVR Post Op uroflow Course After Catheter removal 
24. Lakshmanan  
60/M 
IP:41328 
20 33CC AUR AUR I Grade II left 
lateral  
Grade I 
Right lateral 
Grade I 
median lobe 
28.11.11 POD II 50 ml Qmax – 15 
Qavg-10 
C/o Difficulty in voiding treated with α 
blockers 
25. Shanmugam  
50/M 
IP:43014 
15 48CC Qmax-10 
Qavg-8 
PVR-150 ml II Grade II trilobar  5.12.11 POD II Nil Qmax-12 
Qavg-8 
Developed retention recatheterised 
26. Rangasamy 
65/M 
IP:48676 
 
 
17 60CC AUR AUR III Grade III Lateral 
lobes 
5.12.11 POD II Nil Qmax-10 Qarg-8 Uneventful  
27. Chakrathy 
60/M 
IP:42493 
20 64VV Qmax – 11
Qavg-8 
PVR- 200ml III Grade III Lateral 
lobes 
08.12.11 POD II 45CC Qmax-11 
Qavg-9 
Uneventful  
28. Mani  
60/M 
IP:43035 
19 58CC Qmax-9 
Qavg-6 
100ml III Grade II trilobar 12.12.11 POD II Nil Qmax – 9 
Qavg-7 
C/o. Incontinence  
Taught Kegels exercises, symptom free on 
discharge 
29. Shanmugam  
65/M 
IP: 44100 
27 60CC Qmax-10 
Qavg-6 
75ml II Grade II Lateral 
lobes 
19.02.12 POD II 30 ml Qmax-11 
Qavg-6 
Uneventful 
30. Iyyavoo 
65/M 
IP:421/12 
32 38CC AUR AUR I Grade II Lateral 
lobes 
09.1.12 POD II 40 ml Qmzx-8 
Qar-6 
Developed retention recatheterised  
31. Thangaraj 
57/M 
IP:1265/12 
30 62CC Qmax-9 
Qavg-5 
120ml Ii Grade III trilobar 
enlargement 
30.1.12 POD II 50 ml Qmax-10 
Qavg-6 
Uneventful  
32. Chittaiya 
55/M 
IP:1965/12 
18 35CC Qmax-11 
Qavg-7 
PVR – 150 
ml 
II Grade II lateral 
lobe 
30.1.12 POD-II NIl Qmax-11 
Qavg-8 
Uneventful 
33. Kuttan  
70/M 
IP:2957/12 
21 62CC AUR AUR II Grade II Lateral 
lobes 
2.2.12 POD II 45 ml Qmax-8 
Qavg-6 
Uneventful 
34. Abdul Khadhar 
60/M 
IP:2283 
32 44CC AUR AUR I Grade II lateral 
lobes 
02.02.12 POD II Nil Qmax-8  
Qavg-6 
Uneventful 
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Clinical examination findings on presentation 
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Operative findings 
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Patients feedback 
 
